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Abstract 
Although transdermal drug delivery has been used for about three decades, the range of 
therapeutics that are administered this way is limited by the barrier function of the stratum 
corneum (the top layer of skin). Microneedle arrays have been shown to increase the drug 
permeability in skin by several orders of magnitude by bypassing the stratum corneum. This 15 
can potentially allow the transdermal delivery of many medicaments including large 
macromolecules that typically cannot diffuse through the skin. This paper addresses the use of 
microneedles coated with a drug solution film. In particular, we identify how the geometries 
of various microneedles affect the drug permeability in skin. Effective skin permeability is 
calculated for a range of microneedle shapes and dimensions in order to identify the most 20 
efficient geometry. To calculate effective permeability (Peff), the effective skin thickness (Heff) 
is calculated. These are then plotted for insulin as a model drug to see how various 
microneedle parameters affect the profiles of both Heff and Peff. It is found that the depth of 
penetration from the microneedle array is the most important factor in determining Peff, 
followed by the microneedle spacings. Other parameters such as microneedle diameter and 25 
coating depth are less significant. 
 
Keywords: Effective Skin Permeability, Effective Skin Thickness, Transdermal Drug 
Delivery, Coated Microneedles 
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1. Introduction 
Transdermal drug delivery (TDD) seems to be in clinical use since 1981 (Kumar and Philip, 
2007). The first transdermal patch was developed by Alza Corporation as a treatment for 
motion sickness (Tojo, 1987). Since then, patches have been used in applications such as 
hormonal therapy, pain relief and as an aid to smoking cessation. Such patches allow the 35 
controlled release of drugs over several hours or even days. This is in contrast to bolus drug 
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delivery (i.e., administration of a single large dose), such as by use of a hypodermic needle in 
intravenous delivery whereby the drug is immediately delivered systemically. 
 
Drug delivery via the parenteral route, either by intravenous or intramuscular injection, is 40 
particularly common. Injection by hypodermic needle has been ‘the gold standard’ for drug 
delivery for over a century (McAllister et al., 2003). But, it has a number of disadvantages 
associated with it. Hypodermic needles often cause pain, transmit pathogens through needle 
re-use and require medical expertise to use (Gill and Prausnitz, 2007). Transdermal drug 
delivery is both painless and user-friendly. Another common method of drug delivery is via 45 
the oral route (e.g. taking tablets). However, many drugs such as insulin are severely degraded 
by digestion processes and as such cannot be administered in an oral formulation (Ito et al., 
2006). Drugs administered through TDD avoid gut and first pass liver metabolism, improving 
drug bioavailability (Xie et al., 2005). However, while TDD offers numerous advantages, its 
use has been very limited due to the small range of drugs that can be effectively delivered this 50 
way. Even though blood circulation is close to the skin surface, the skin is very well adapted 
to prevent infectious substances entering the body. This is largely due to the outer layer of 
skin, the stratum corneum. In order to passively diffuse through this layer, drug molecules 
must be of a low molecular weight (< 500Da) and hydrophobic. Even if these conditions are 
met, the drug must be potent so that the small amounts that can be delivered are sufficient 55 
(Gill and Prausnitz, 2007). 
 
When considering a model for transdermal diffusion, it is usually assumed that the skin acts 
as a bi-layer membrane which consists of the stratum corneum and the viable skin. Drug that 
permeates through the viable skin is rapidly absorbed by the microcirculation (Tojo, 1987). It 60 
is clear that the stratum corneum is the main barrier to diffusion through the skin. The 
diffusion coefficient of drug molecules within the stratum corneum is usually at least 500 -
10,000 times smaller than within the viable skin (Tojo, 1987). In general, there are several 
ways in which its barrier ability can be reduced or bypassed and hence achieving better 
transdermal drug delivery. These include electroporation (Sen et al., 2002), phonophoresis 65 
(Mitragotri et al., 1995), sonophoresis (Merino et al., 2003) and chemical enhancers 
(Williams and Barry, 2004). However, the range of drugs that can be incorporated into such 
drug delivery systems is limited by the barrier function of the skin.  The outer layer, or 
stratum corneum, which is rate-limiting for transdermal transport, has been shown to be the 
main obstacle for high molecular weight drugs to diffuse through the skin (Badkar et al., 70 
2007). Therefore, most drug molecules with high molecular weight are unable to effectively 
enter the bloodstream. 
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In addition to the methods mentioned previously, skin permeability can also be enhanced 
through the use of microneedles (Kim and Lee, 2007). Arranged into an array, these are 75 
micron-scale projections that penetrate through the stratum corneum, creating a superficial 
pathway through which drugs can reach the deeper levels of the skin. The working principle 
of the microneedle arrays has been discussed in a number of previous papers (Prausnitz, 2004; 
Al-Qallaf et al., 2007). Till date, four methods of transdermal delivery mediated by 
microneedles have been attempted (Gill and Prausnitz, 2007): 80 
 
 (i) Applying an array of microneedles to first permeabilize the skin before using a traditional 
transdermal patch. 
(ii) Coating the microneedles with a drug containing film before inserting into the skin. 
(iii) Creating the microneedles from a polymeric material that contains the drug. The drug is 85 
then released in a controlled manner after insertion into the skin. 
(iv) Injection through hollow microneedles. 
 
The first three methods utilise solid microneedles and the last method relies on a liquid 
formulation being injected through hollow microneedles. Hollow microneedles have generally 90 
received less attention to date as they are inherently structurally weaker and have practical 
problems such as the bore hole being clogged by tissue (Wang and Cornwell, 2006). This 
paper will focus on the second method, the so-called “coat and poke” approach (Prausnitz, 
2004) as shown in Figure 1. 
 95 
Recently, there has been an interest to investigate the influences of a variety of variables 
related to the microneedles to reach the optimum microneedle design and hence, improve the 
transdermal drug delivery when using microneedle arrays. Many relevant factors have been 
considered to formulate an optimized microneedle arrays, including the mask shape of the 
microneedle (Wilke and Morrissey, 2007), location of the microneedle hole (Khumpuang et 100 
al., 2007), the microneedle tip radius (Teo et al., 2006), etc. However, most of these studies 
made their decision based on different criteria such as microneedle insertion, but not skin 
permeability, although skin permeability has been considered as a key factor that determines 
the efficiency of transdermal drug delivery process (Wilke et al., 2006). 
 105 
Our previous study showed the effect of various parameters (e.g., number of microneedles, 
microneedle radius, etc) influencing the permeability of skin (Al-Qallaf and Das, 2007). This 
has been done by developing an optimization algorithm to determine the optimum 
microneedle dimensions of both hollow and solid microneedles. Skin thickness based on 
different classifications (e.g., race, sex, etc) has been correlated with skin permeability (Al- 110 
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Qallaf and Das, 2007). In another study, we proposed a mathematical framework which 
provides quantitative evaluations of various parameters influencing the drug concentration in 
blood (Al-Qallaf et al., 2007). A scaling analysis has also been done which describes the 
functional dependency of drug concentration on other variables of skin and microneedle 
arrays (Al-Qallaf et al., 2007). Following from these studies, this work aims  to quantify the 115 
influence of various geometrical parameters (e.g., microneedle thickness, coating depth, etc) 
associated with six microneedle shapes of coated drugs on the effective skin permeability 
with a view to identify the most effective geometry of the micro-needles. The ratio (RP) of 
drug permeability with microneedles to the permeability of normal skin (i.e., without 
microneedle arrays) has also been determined. This has been done to obtain more information 120 
for designing microneedle arrays since that little quantitative research has been presented for 
determining skin permeability using microneedles (Wu et al., 2006). This ratio helps to assess 
the ability of increasing skin permeability using microneedles. This parameters seems to be 
useful to compare various microneedles model, and hence, to achieve the optimum geometry. 
 125 
2. Modelling Strategy  
2.1 Model Assumptions 
For the purpose of this work, the following assumptions are made: 
(1) The concentration of the drug (C) in the blood remains low throughout, and so the 
blood is considered to act as a sink, i.e. C = 0 for all time (t). 130 
(2) Skin binding is assumed to be negligible in the viable skin. 
(3) Drug metabolism is assumed to be negligible in the viable skin. 
(4) All drug molecules that diffuse through the viable skin are taken up by the 
microcirculation. 
(5) The rate limiting step is diffusion through the viable skin. 135 
The first assumption can be considered to be realistic as drug coating solutions are generally 
many orders of magnitude greater than the drug plasma concentration. Skin binding involves 
drug molecules becoming bound to active sites on macromolecules, which can cause a 
reduction of the diffusion coefficient to an ‘effective value’ that is a function of drug 
concentration (Tojo, 2005). Drug binding tends to be prevalent in the stratum corneum rather 140 
than the viable skin, so ignoring it is a reasonable approximation. 
 
Metabolism by the living cells in the viable skin however can lead to an appreciable decrease 
in the systemic delivery of the drug (Tojo, 2005). To our best knowledge, there is no data to 
quantify the effect of skin metabolism on various drugs, particularly for those drugs that have 145 
not typically been used in transdermal delivery before. In one study, the pharmacological 
availability of insulin delivered by drug-loaded polymer microneedles was found to be 
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between 91-98% when compared to intravenous dosing. In many practical cases, it may be 
possible to prevent metabolism, as demonstrated by Sintov and Wormser (2007). Iodine was 
used to deactivate skin glutathione so that insulin could retain its potency as it permeated 150 
through. As the objective of this paper is to compare microneedle designs, metabolism of 
drugs in the viable skin is ignored for simplicity. 
 
The fourth assumption defines that 100% of the drug molecules that diffuse into the area of 
skin occupied by the microcirculation (taken to be 200 µm deep) are absorbed into the blood.  155 
This is a common assumption and is considered realistic (see, e.g., Tojo, 1987). 
 
The final assumption defines that the rate at which the drug dissolves into the tissue fluids and 
the rate at which it is absorbed by the blood is rapid compared to the rate at which it diffuses 
through the viable skin. This is a fair approximation, as the coating should be a mainly 160 
aqueous solution and will quickly dissolve into the skin’s tissues (i.e., within 20 seconds) 
according to Gill and Prausnitz (2007). Drug molecules should also be quickly absorbed into 
the blood, especially in vivo (Tojo, 1987). 
 
2.2.1 Governing Equations for Drug Transport in Skin 165 
For solid microneedles coated by an aqueous solution of drug molecules, the rate-limiting step 
is the transport of drugs through the viable epidermis. Drug molecules dissolve in the 
interstitial fluids of the skin and diffuse towards the microcirculation in the dermis. It is 
assumed that absorption by the blood is rapid compared to permeation through the skin (Tojo, 
1987). In order to determine the effective skin permeability, and hence, the effective skin 170 
thickness, Fick’s first law has been adopted: 
dx
dCDJ −=            (1) 
Where J is the flux of drug through the skin, D is the diffusion coefficient of drugs in skin, C 
is the concentration of diffusing drug and 
dx
dC
 is the concentration gradient. 
At steady state (i.e. 0
dt
dC = ) it can be defined that,   175 
=
dx
dC
constant
H
CC 12 −=         (2) 
Here, H is the thickness of the skin after microneedles have been inserted, C2 is drug 
concentration at the bottom of epidermis layer and C1 is drug concentration at the tip of 
microneedles. Now, combining Fick’s first law (equation 1) with equation (2), we obtain an 
expression for steady state diffusive flux Jss as follows: 180 
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)CC(
H
DJ 12ss −−=         (3) 
)CC(PJ 12ss −−=         (4) 
Where P is the drug permeability in skin. When C2 is defined to be zero (i.e., sink condition) 
Jss is given by: 
1ss PCJ =          (5) 185 
For coated microneedles, the drug permeability is increased by bypassing the stratum 
corneum. This leaves the drug to diffuse across the viable skin (which consists of the viable 
epidermis and dermis) into the blood microcirculation. Assuming steady state transport across 
skin (Park et al., 2005), the effective permeability Peff of the skin when coated microneedles 
are being used is calculated by: 190 
eff
vs
eff H
D
P =          (6) 
Where Dvs is the diffusion coefficient of the drug in the viable skin which is assumed to be 
constant (i.e., the diffusion coefficients in the viable epidermis and dermis are of the same 
magnitude) (Tojo, 1987) and Heff is the effective thickness of the skin after microneedles have 
been inserted. Therefore, Heff is a function of purely of microneedle geometry. 195 
 
2.2.2 Skin Permeability (without microneedles arrays) 
The effective permeability of a drug due to microneedles can be compared with its 
permeability through normal skin that has its stratum corneum intact. By considering the skin 
to act as a bilayer membrane (Tojo, 1987), the permeability of intact skin is found by 200 
reciprocal addition of the permeability of the two layers, the stratum corneum and viable skin 
as follows: 
 
vsscskin P
1
P
1
P
1R +==        (7) 
scvsvssc
vssc
skin HDHD
DD
P ×+×
×=       (8) 
Where R is the resistance, Pskin is skin permeability, Dsc and Dvs are diffusion coefficients of 205 
stratum corneum and viable skin, respectively while Hsc and Hvs are thicknesses of stratum 
corneum and viable skin, respectively. The resistance implies the inverse of permeability. 
 
The ratio (RP) of permeability with microneedles to the permeability of normal skin is given 
by dividing equation (8) by equation (6) as follows: 210 
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eff
scDvs
p H
HRH
R
×+=        (9) 
Where, RD is the ratio of diffusion coefficients in the viable skin and stratum corneum. This 
value is typically 500 – 10,000 (Tojo, 1987). 
 
2.3 Microneedles Models 215 
For the purpose of this work, six microneedle shapes have been chosen, as shown in Table 1 
and Figure 2. The shapes have been chosen according to what has been seen in literature, 
although the exact dimensions are not the same. Microneedle model A consists of a 
cylindrical shaft with a cone tip. Needles of this form have been constructed by Xie et al. 
(2005). The standard dimensions are shown in Figure 2(A). Whenever the dimensions are 220 
varied, the tip angle is maintained at 45°. Microneedle model B is a cone shape. An example 
of this type of needle can be seen in Figure 2(B), fabricated by Henry et al. (1998). As the 
geometry is varied, the tip angle is maintained at 79.9°. Microneedle model C is a cylinder 
with a bevelled tip. An example of such a microneedle is shown in Figure 2(C), fabricated by 
McAllister et al. (2003). The standard dimensions are also shown. As the geometry is varied, 225 
the bevel angle of 45° is maintained. Microneedle model D is shown in Figure 2(D) with its 
standard dimensions, along with an example of this type of needle from Gill and Prausnitz 
(2007). The tip angle is maintained at 45°. Microneedle model E is an ‘arrow-head’ type 
needle manufactured by Gill and Prausnitz (2007) as shown in Figure 2(E). The arrow-head 
length and tip angle of 53.1° is maintained as the microneedle geometry is varied. 230 
Microneedle model F is a triangular type microneedle proposed by Martanto et al. (2004) as 
shown in Figure 2(F). The tip angle is maintained at 79.9° as the geometry is varied. 
 
2.4 Method of solution 
Drug diffusion from coated microneedles is modelled in 3D using FEMLAB, a piece of 235 
scientific modelling software from Comsol (Comsol, 2005). It allows equation-based 
multiphysics modelling in an interactive environment. Free-form partial differential equations 
can be set up or particular physics applications can be chosen, in this case diffusion. 3D 
geometry of the microneedles can then be drawn and the diffusion of drug molecules analysed 
in transient or steady state. This is done by performing finite element analysis on the domain 240 
of interest. The domain is discretised into a mesh of small 3D elements, usually tetrahedrons. 
Our results show that the mesh is accurate enough, so that refining it did not significantly 
change the results. Boundary conditions and subdomains parameters are set and the PDE’s 
that characterise the physics of the domain are converted into ordinary differential equations.  
 245 
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In order to model the diffusion process from the coated microneedles into the skin, the 
diffusion model was used in FEMLAB as shown in Figure 3 where the standard dimensions 
for the FEMLAB model, in this case are microneedle model A. CD is the coating depth of 
drug on the microneedle (i.e., the distance from the tip that is coated by the drug film). As a 
standard, this is 100 µm, as seen in literature (Widera et al., 2006). S is the width and length 250 
of the square element of skin. It also represents the centre-to-centre spacing of the 
microneedles, assuming they are in a square pattern. As a standard, this distance was 100 µm. 
The distance to the microcirculation from the skin surface has been reported as 200 µm (Tojo, 
1987) and so that is used here. Similarly other models were also set up based on Table 1 and 
Figure 2. 255 
 
The skin is modelled as a single subdomain with an isotropic diffusion coefficient (D). It was 
found that having a layer to represent the stratum corneum did not significantly affect the 
results and so it is not included in the model for simplicity. The blood is assumed to act as a 
sink for the drug and so this boundary condition is set (concentration is set to zero on this 260 
boundary). 
 
The boundary conditions for the drug concentration at the surface of the coated microneedle 
are, 
0tforLxLatCC ua ><<=      (10) 265 
On the other hand, the boundary condition for the drug concentration at the bottom of the 
epidermis layer is,  
0tforhxat0C >==      (11) 
Where aC is the drug concentration at the surface of the coated drug, uL is the uncoated 
microneedle length, L is the microneedle length, h is the epidermis thickness (i.e. equal to 200 270 
µm), x is the distance in a given skin layer and t is time. 
 
We calculate the steady state diffusive flux of drug through the blood interface assuming the 
concentration of drug on the needle is constant. It allows the calculation of effective skin 
thickness Heff, which is purely dependent on microneedle geometry. In our approach, Heff is 275 
calculated using the following method. The flux term determined from the simulations is 
integrated over the microcirculation boundary and then divided by the boundary area to give 
an average steady state flux, Jss. By rearranging the steady state of Fick’s first law, the 
following expression is found: 
ss
avs
eff J
CDH ×=         (12) 280 
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Where aC is the drug concentration at the surface area of the coated drug and Heff can then be 
used to calculate the effective skin permeability Peff in equation (6). It is assumed that the drug 
concentration at the surface area of the coated drug is 1% (w/v), which is 1 g/100 ml. This is a 
typical value from the work by Gill and Prausnitz (2007). This value was kept the same in all 
cases. 285 
 
By symmetry, it is possible to model a whole array of microneedles by modelling only a 
single microneedle. For instance, it can be shown that the flux of drug from one microneedle 
only needs to be multiplied by the number of microneedles in the array to give the total flux 
of drug. For example, an array of nine microneedles can be represented by the modelling a 290 
single microneedle, due to symmetry. This is convenient as the geometry of the problem 
becomes considerably simpler. 3D modelling of complex geometry requires greater computer 
processing power and takes longer simulation time. 
 
3. Results and Analyses 295 
In the present work, the following geometrical parameters of the microneedles were varied: 
depth of penetration, diameter (microneedle models A and C), thickness (microneedle models 
D and E), coating depth, center-to-center spacing. In addition, hexagonal symmetrical 
elements were designed for microneedle models A and B to compare with the case of square 
elements. Skin is wrinkled and has various surface features such as hairs. In addition to the 300 
visco-elasticity of the skin, this means that microneedles will not penetrate to their full length 
(McAllister et al., 2003). In general, microneedles longer than 100 µm should be used to 
ensure that they penetrate beyond the stratum corneum (Stoeber and Liepmann, 2005). As the 
microcirculation is located ~200 µm beneath the skin’s surface in general, the microneedles 
should be shorter than this to prevent any chance of bleeding. For these reasons, the 305 
microneedles in the model are varied between 100-180 µm. The microneedle diameter ranges 
from 30-70 µm and the thicknesses between 25-75 µm. The diameter of microneedle model B 
was not varied as the tip angle of 79.9° must be maintained and a change in diameter would 
not be possible without a change in penetration depth. Coating depth ranges between 40-120 
µm and centre-to-centre spacing ranges between 75 – 200 µm. These ranges have been chosen 310 
based upon typical values seen in literature. 
 
3.1 Effects of  depth of penetration 
The ability of controlling the depth of penetration has a significant limitation when using the 
microneedles of different geometries (Matriano et al., 2002). It is therefore important to relate 315 
microneedle dimensions to the penetration depth which then influence the performance of the 
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microneedles for drug delivery process (Teo et al., 2005). Widera et al. (2006) showed that 
coated microneedles with different drug doses did not decrease the penetration depth for a 
given microneedle length. However, the depth of penetration decreased with increased 
microneedles length for a given dose (Widera et al., 2006). In contrast, Cormier et al. (2004) 320 
compared the penetration depth for both coated and uncoated microneedles. In their study, 
they found a significant reduction in penetration depth for coated microneedles. 
 
To address this issue in a systematic manner, the depth of microneedle penetration was varied 
for all types of microneedle to calculate the effective skin thickness Heff and effective skin 325 
permeability Peff of insulin as a model drug (Dvs= s/cm101 210−× ; Lv et al., 2006). 
Microneedle length in this model represents the depth to which the microneedle penetrates the 
skin, and as such, does not directly represent the physical length of the microneedle. Besides 
depth of penetration, the standard dimensions in Table 1 are used in all of the microneedle 
models and the results are shown in Figure 4. There is an obvious linear relationship between 330 
Heff and microneedle penetration depth for all the models. The data points for both 
microneedles models A and C are indistinguishable due to the similarity in their geometry. 
For this reason, the data for microneedle model C is not plotted. The linear result is a 
consequence of the fact that the average diffusion path length becomes shorter in proportion 
to the depth of penetration. For a given length, the effective skin permeability is the maximum 335 
for microneedle model D and the minimum for microneedle model B. The geometry of 
microneedle model D is such that its tip has a relatively large surface area and thus presents a 
larger amount of drug closer to the microcirculation. This reduces the effective skin thickness 
and increases the effective permeability. 
 340 
3.2 Effects of  microneedle diameter 
Rajaraman and Henderson (2005) argued that the microneedle diameter depends on the 
materials used for fabrication. The experimental results conducted by Stoeber and Liepmann 
(2005) illustrated that microneedle diameter depends on the maximum microneedles density 
(i.e., number of microneedles per unit area). The force needed to cause microneedle failure 345 
during piercing through skin increases by increasing microneedle diameter (Park et al., 2007). 
These results were consistent with the simulations presented by Haider et al. (2001) where the 
insertion force requirements increased with increasing microneedle diameter. Teo et al. 
(2005) demonstrated that increasing microneedle diameter improved transdermal drug 
transport. Microneedles tend to buckle for a given diameter and length by increasing 350 
microneedles length but of the same diameter at pressure less than that needed to penetrate the 
stratum corneum (Mukerjee et al., 2004). Microneedle with larger diameter provides higher 
 11
mechanical stability than that with a smaller diameter (Ovsianikov and Chichkov, 2007). 
Khumpuang et al. (2005) fabricated microneedles array with a microneedle diameter of 40 
µm to prevent any problems appear in blood clogging due to the small diameter of while 355 
blood cell (i.e., approximately more than 20 µm). 
 
Following the above discussions, we investigated the influence of various microneedle 
diameters on both the effective skin thickness and effective skin permeability for various 
geometries. Figure 5 was obtained when the diameters of microneedles model A and model C 360 
were varied. Besides diameter, the other dimensions are standard values (penetration depth = 
140 µm, coating depth = 100 µm, microneedle spacing = 100 µm). It can be seen in Figure 5 
that by increasing the diameter, the effective skin thickness is decreased, increasing the 
effective skin permeability. However, over the range of diameters tested, the effective skin 
thickness only changed by less than 10%, indicating the effective skin thickness is not a 365 
strong function of the diameter. As the diameter is increased, the diffusion paths from the 
microneedle to the corners of the microcirculation interface are reduced. This is responsible 
for decreasing effective skin thickness and increasing effective skin permeability. Diameter 
may be more important in increasing the available surface area for drug coating on the 
microneedle. Effective skin permeability appears to tend to a constant value as diameter is 370 
increased. For a given diameter, there is little difference in the effective skin permeability 
when either microneedle is considered. This is presumably due to the similarity of geometry 
in the two models. 
 
3.3 Effects of  microneedle thickness 375 
The thickness of microneedle has been considered as an important parameter, since it is 
related to the length of microneedles and hence its strength (Rajaraman and Henderson, 
2005). Davis et al. (2004) found that the force of microneedle fracture depends on the 
microneedle thickness. They noticed that the margin of safety (i.e., ratio between microneedle 
fracture and skin insertion force) reached its highest value with large microneedle thickness. 380 
 
To determine the effects of this parameter, the thickness of microneedle models D-F was 
varied and the results are shown in Figure 6. Standard dimensions were used in Table 1. The 
results indicate that by increasing the thickness of these microneedles, effective skin thickness 
will decrease and permeability will increase. The range of effective skin thickness is quite 385 
small for each microneedle (13-15%) when compared to the range that was obtained by 
varying length (>60%). This indicates effective skin thickness is a relatively weak function of 
thickness, like diameter. Unlike in the case of diameter though, effective skin permeability 
appears to be a linear function of thickness. The mechanism by which permeability is 
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increased is probably due to the shortening of diffusion paths from the microneedle to the 390 
corners of the microcirculation interface in the skin diffusion model. 
  
3.4  Effects of microneedle drug coating depth 
Gill and Prausnitz (2007) examined the ability of controlling the microneedle length by 
varying the coverage coating percentage of the microneedle length. However, they did not 395 
study the influence of this variation on skin permeability. Widera et al. (2006) studied the 
effect of changing the coating dose for four microneedle array designs. They found that both 
the length and density of microneedles did not influence the total amount of drug delivered 
into the skin. The amount delivered of ovalbumin as a model protein increased as a result of 
increasing the coating concentration of ovalbumin (Matriano et al., 2002). However, 400 
decreasing the coating dose would improve the drug delivery efficiency (Cormier et al., 
2004). 
 
In this study, the depth of drug coating was varied on all microneedles (with otherwise 
standard dimensions), between 40 to 120 µm. The effect on effective skin thickness and 405 
permeability are shown in Figure 7. For all cases, except microneedle model B, effective skin 
thickness and skin permeability are very weak functions of the coating depth of the drug film 
on the microneedle. As mentioned before, microneedle model A and microneedle model C 
were found to be indistinguishable so microneedle model C is not plotted. Beyond 60-80 µm 
it seems that effective skin thickness and effective skin permeability become independent of 410 
coating depth. It is difficult to explain why coating depth appears to be more important in 
determining effective skin permeability for microneedle B than the other models. 
 
3.5 Effects of  microneedle spacing 
As expected, the center-to-center distance between two adjacent microneedles is an important 415 
factor for fabricating microneedles (Choi et al., 2006). The insertion force of microneedles 
depends on microneedles spacing (Parker et al., 2007). This accords well where the insertion 
force of microneedles depends on microneedles spacing as well as microneedle length (Davis 
et al., 2004). They suggest that the insertion force depends also on the number of 
microneedles as long as the spacing is wide enough. Increasing the center-to-center spacing 420 
improves the transdermal drug delivery efficiency of coated microneedles (Gill and Prausnitz, 
2007). Haider et al. (2001) also demonstrated this by increasing microneedle spacing which 
reduced penetration force. While the previous studies attempted to determine effects of micro-
needle spacing on the force of insertion, it not clears how the spacing influences the effective 
skin permeability and thickness. 425 
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To address this issue in this work, the centre-to-centre spacing was varied between 75-200 µm 
for all the microneedle models (with standard dimensions). From Figure 8, it appears that an 
exponential relationship exists between microneedle spacing and both effective skin thickness 
and effective skin permeability. When each series of data is fitted to an exponential trend line, 430 
the R2 value is greater than 0.99, indicating a strong agreement. As spacing increases, the 
surface area of the microcirculation interface (where the sink condition exists) in each square 
symmetrical element of the microneedle array also increases. The diffusion paths from the 
microneedle surfaces in the centre of the element to the corners of the microcirculation 
interface become longer as the area of the interface increases. This is responsible for the 435 
increase in effective skin thickness and hence the decrease in effective skin permeability. As 
stated before, the data for microneedle model C was indistinguishable from microneedle 
model A and so was not plotted. 
 
3.6 Square or hexagonal microneedle array pattern 440 
Since the first fabrication of microneedles, different microneedles array patterns have been 
proposed such as square (Hsu et al., 2007), hexagonal (Widera et al., 2006), etc. However, the 
shape of the pattern does not represent the shape of microneedle cross section (Rodriguez et 
al., 2005). In this work, it was determined whether arranging the microneedles into a 
hexagonal pattern affected the effective permeability of skin. This was done by using 445 
hexagonal shaped elements in the skin diffusion model instead of square ones. Therefore, the 
demonstration has been done for microneedle models A and D. Figure 9 indicates that for a 
given centre-to-centre spacing, effective skin permeability is slightly greater when a 
hexagonal array pattern is used over a square pattern. As mentioned previously, the relation 
between effective skin thickness and effective skin permeability with microneedle spacing is 450 
an exponential increasing and decaying, respectively. For a given centre-to-centre 
microneedle spacing, the area of the microcirculation interface is greater for square elements. 
As a result, the diffusion paths are then longer which results in a greater effective skin 
thickness. 
 455 
3.7 Effects of  increase in skin permeability relative to untreated skin 
Microneedle arrays have been considered as an intelligent drug delivery devices (Tao and 
Desai, 2003). Over the past few years, a variety of methods have been proposed to determine 
the skin permeation of drugs caused by microneedles. Wu et al. (2006) used macroneedles 
instead of microneedles and determined permeability through treated skin by macroneedles. 460 
Wu et al. (2007) compared permeability of high molecular compounds through treated skin 
by microneedle before and after applying the iontophoresis. This has been done by evaluating 
permeability factor (i.e., ratio of flux through fresh intact skin over flux post-iontophoresis). 
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However, as far as the authors know, no theoretical effort had ever been done for evaluating 
the relative skin permeability to quantify the changes before and after applying the 465 
microneedles across skin. For that reason, we determine the ratio of permeability with 
microneedles and permeability of normal skin (RP) which is a function of Heff, the effective 
skin thickness and RD, the ratio of diffusion coefficients in the viable skin and stratum 
corneum. As mentioned previously, the value of RD varies between 500 -10,000 (Tojo, 1987). 
The thickness of stratum corneum and viable skin were assumed to be 20 µm and 180 µm, 470 
respectively. This has been assumed since that the distance to the microcirculation from the 
skin surface has been reported as 200 µm (Tojo, 1987). Figure 10 shows how RP varies as a 
function of Heff for particular values of RD. The range of Heff corresponds to the range 
calculated in the previous section. The permeability of skin is increased by around 3 orders of 
magnitude compared to normal untreated skin (i.e., Rp ranges from 63 – 6673). This result is 475 
consistent with literature, which states that microneedles can improve skin permeability by 
over 1000 times when left in place (Henry et al., 1998). 
 
4. Conclusions 
The geometry effects of various types of solid microneedles with insulin as a model drug have 480 
been discussed in this paper. A framework has been presented in this paper to identify the best 
microneedle models used in transdermal drug delivery to increase skin permeability. 
Microneedle model D was the best model in terms of penetration depth, microneedle 
thickness, coating depth and center-to-center spacing while, microneedle model A was the 
best model in terms of microneedle diameter. Effective skin thickness (Heff) and permeability 485 
(Peff) were calculated for various microneedle models. It was found that microneedle 
penetration depth was the most significant factor in determining these parameters. This is 
expected, as deeper microneedle penetration will directly shorten the drug diffusion paths 
from the microneedle surfaces into the microcirculation of the skin. Centre-to-centre spacing 
of the microneedles in the array also had a significant effect on effective permeability. The 490 
other microneedle dimensions, the diameter in cylindrical needles, the thickness in flat 
needles, and the coating depths were less significant in determining Peff. In general, larger, 
longer and more densely packed microneedles will result in greater skin permeability, which 
is an intuitive result. Skin permeability was seen to be enhanced by around 3 orders of 
magnitude through use of microneedles in the model, which is consistent with practical 495 
studies. This suggests that for designing microneedle arrays, considering the geometries of the 
microneedle arrays enhance efficiency of transdermal drug delivery techniques. The proposed 
relationship of both effective skin permeability and skin thickness allow us to predict the 
permeation across human skin and to correlate the microneedles geometries to deliver 
low/high molecular weight drug using microneedles. Further work should include practical 500 
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experimental data and clinical trials to determine whether the models from this research 
accurately represent the real situation. 
 
5. Acknowledgment 
The authors would like to thank MOI (Ministry of Interior), Kuwait for funding this work. 505 
 
6. Nomenclature 
C Concentration of diffusing drug (units.m-3) 
C1 Drug concentration at the tip of microneedle (units.m-3) 
C2 Drug concentration at the bottom of epidermis layer (units.m-3) 510 
Ca Drug concentration at the surface of the coated drug (units.m-3) 
CD Coating depth of drug on the microneedles (µm) 
D Diffusion coefficient of drug in skin (m2.s1) 
Dsc Diffusion coefficient of drug in the stratum corneum (m2.s1) 
Dvs Diffusion coefficient of drug in the viable skin (m2.s1) 515 
H Thickness of the skin after microneedles have been inserted (µm) 
Heff Effective skin thickness of the skin after microneedles have been inserted (µm) 
Hsc Thickness of the stratum corneum (µm) 
Hvs Thickness of the viable skin (µm) 
h Thickness of the epidermis (µm) 520 
J Flux of drug through the skin (units.m-2.s-1) 
Jss Steady-state diffusion flux (units.m-2.s-1) 
L Microneedle length (µm) 
Lu Uncoated microneedle length (µm) 
P Drug permeability in skin (µm.s-1) 525 
Peff Effective permeability of the skin when coated microneedles are being used (µm.s-1) 
Pskin Skin permeability (µm.s-1) 
RD The ratio of diffusion coefficients in the viable skin and stratum corneum (−) 
Rp The ratio of drug permeability with microneedles to the permeability of normal skin 
(without microneedles) (−) 530 
S The width and length of the square element of skin (µm) 
t Time (s) 
x The distance in a given skin layer (µm) 
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Table 1. The design parameters of each microneedle model.
Model Figure No. Penetration depth (µm) Diameter/Width Microneedle thickness (µm)  Center-to-center spacing (µm) Coating depth (µm) Number in array
A 2A 140 50 N/A 100 100 200 
B 2B 140 50(at base) N/A 100 100 200 
C 2C 140 50 N/A 100 100 200 
D 2D 140 50 35 100 100 200 
E 2E 140 30(shaft) and 60(tip) 35 100 100 200 
F 2F 140 50 35 100 100 200 
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Figure 1. Schematic of coated microneedles for transdermal drug delivery. Lu is the uncoated 
microneedle length, L is the total microneedle length, h is the epidermis thickness and H is the 
thickness of the skin after microneedles have been inserted, i.e., the distance between micro-
needle tip and the blood micro-circulation. 
Stratum corneum 
Viable epidermis 
x=h 
H
x=Lu 
x=L 
Skin surface 
C=0 (Sink condition) 
Coated microneedle 
           C=Ca 
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Figure 2. The different microneedles models used for coating drugs. (A) was fabricated by Xie et al. 
(2005), (B) was fabricated by Henry et al. (1998), (C) was proposed by McAllister et al. (2003), (D) & 
(E) were fabricated by Gill and Prausnitz (2007) and (F) was fabricated by Martanto et al. (2004).
A C
D E 
F
B 
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Figure 3. A schematic model for modelling diffusion from a microneedle through the skin: (a) 
3D view, (b) side view and (c) top view. CD is the coating depth of drug on the microneedle 
and S is the width and length of the square element of skin.
(a) (b) (c) 
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Figure 4. Influence of the changing penetration depth of various microneedles models, coated with 
insulin, on effective skin thickness Heff (solid markers) and effective skin permeability Peff (blank 
markers). 
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Figure 5. Influence of the microneedle diameter of insulin coated microneedles models on the effective 
skin thickness Heff (solid markers) and effective skin permeability Peff (blank markers). 
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Figure 6.  Influence of microneedle thickness of insulin coated microneedles models on effective skin 
thickness Heff (solid markers) and effective skin permeability Peff (blank markers).
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Figure 7. Influence of microneedle coating depth of insulin for various microneedles models on 
effective skin thickness Heff (solid markers) and effective skin permeability Peff (blank markers). 
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Figure 8. Influence of insulin coated micro-needle spacing on the effective skin thickness Heff (solid 
markers) and effective skin permeability Peff (blank markers).
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Figure 9. Comparison of the effects of insulin coated microneedle spacing for models A and D for 
square and hexagonal microneedle patterns on effective skin thickness Heff (solid markers) and 
effective skin permeability Peff (blank markers). 
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Figure 10. The relative permeability of treated skin to untreated skin (Rp) as a function of the ratio of 
diffusion coefficients in the viable skin and stratum corneum (RD) and the effective skin thickness 
(Heff). Rp (-) is the ratio of drug permeability with microneedles to the permeability of normal skin (i.e., 
without microneedles). 
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